ArticleJournal of robotic surgery2026
3D surgical navigation contributes to renal function preservation during robot-assisted partial nephrectomy.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Robot-assisted partial nephrectomy (RAPN) requires a precise resection plane to minimize parenchymal loss while preserving oncological safety. A 3D virtual navigation system showed precision advantages in a prior phase I study. We aimed to validate these findings in an expanded cohort and examine whether benefits differ by tumor complexity. In this single-center cohort study, 30 consecutive patients prospectively enrolled to undergo navigation-assisted RAPN (2024-2025) were matched with historical controls (2017-2022) by selecting two patients with the nearest clinical tumor size per case, following exact matching for RENAL nephrometry score. The primary endpoint was excess resected parenchyma (resected specimen volume minus tumor volume); secondary endpoints were 3-month declines in serum eGFR and DTPA-measured ipsilateral GFR. Outcomes were compared overall and by complexity subgroup. After matching, baseline characteristics were well balanced. Excess resected parenchyma was significantly lower in the navigation group (2.7 vs. 6.2 cm³, p = 0.013), and this difference persisted after multivariable adjustment for surgical approach, RENAL nephrometry score, and clinical tumor size (β = -3.39 cm³, 95% CI -6.05 to -0.73; p = 0.013). Lower serum eGFR decline (6.0% vs. 10.8%) and DTPA-measured ipsilateral GFR decline (21.4% vs. 26.0%) in the navigation group were observed but neither difference reached statistical significance. No intraoperative complications or positive surgical margins occurred in either group. The reduction in excess resected parenchyma appeared greater in the high-complexity subgroup (Navigation n = 2, Control n = 4; 2.7 vs. 8.9 cm³) than in the low-complexity subgroup (1.7 vs. 4.3 cm³); however, the group × complexity interaction was not statistically significant (p > 0.1). Navigation-assisted RAPN significantly reduced excess parenchymal resection, an anatomical surrogate of long-term renal function preservation. A possible trend toward greater benefit in higher-complexity tumors observed in our study warrants confirmation in larger, complexity-stratified, multicenter studies.
Indexed as
Identifiers
42201407What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.